Press Releases Oncopeptides AB

Equities

ONCO

SE0009414576

Real-time Estimate Cboe Europe Other stock markets 08:27:55 2024-05-10 EDT			5-day change	1st Jan Change
2.948 ^SEK	+1.48%		-0.50%	-61.29%

04-15	Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	CI
04-04	Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncopeptides publishes final outcome in the fully guaranteed rights issue	05-06	AQ
Annual General Meeting in Oncopeptides AB (publ)	04-29	AQ
Oncopeptides publishes the 2023 Annual Report	04-22	AQ
Oncopeptides publishes prospectus relating to the rights issue	04-17	AQ
Bulletin from an Extraordinary General Meeting in Oncopeptides AB (publ)	04-15	AQ
Oncopeptides secures national reimbursement for Pepaxti in Spain	04-15	AQ
Oncopeptides announces final terms for the fully guaranteed rights issue	04-08	AQ
Oncopeptides releases first quarter 2024 sales	04-04	AQ
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	03-27	AQ
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	03-27	AQ
Extraordinary General Meeting in Oncopeptides AB (publ)	03-13	AQ
Oncopeptides : Oncopeptalks on the company's rights issue	03-13	PU
Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 300 million to reach profitability during 2026	03-13	AQ
FDA Flexes Its New FDORA Muscles In Withdrawing An Accelerated Approval	03-08	AQ
Oncopeptides PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration	03-04	AQ
Oncopeptides : to present at two investor events	03-04	PU
Oncopeptides AB - Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica	03-01	AQ
Oncopeptides' : PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration	03-01	PU
Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration	03-01	AQ
Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica	02-29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oncopeptides AB

Equities

ONCO

SE0009414576

Press Releases

Filters